Predictive role of polymorphisms in interleukin-5 receptor alpha-subunit, lipoprotein lipase, integrin A2 and nitric oxide synthase genes on ischemic stroke in type 2 diabetes-An 8-year prospective cohort analysis of 1327 Chinese patients

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 130-135

  Luk, Andrea O Y ^a   Wang, Ying ^a   Ma, Ronald C W ^a   Tam, Claudia H T ^a   Ng, Maggie C Y ^a   Lam, Vincent ^a   Yang, Xilin ^a   Baum, Larry ^a   Tong, Peter C Y ^a   Chan, Juliana C N ^a   So, Wing Yee ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Genetic polymorphisms; Stroke; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTEGRIN; INTEGRIN A2; INTERLEUKIN 5 RECEPTOR ALPHA; LIPOPROTEIN LIPASE; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTEGRIN ALPHA2; INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STROKE;

EID: 79952106170     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.042     Document Type: Article

References (30)

1. Harmsen P., Lappas G., Rosengren A., Wilhelmsen L. Long-term risk factors for stroke: Twenty-eight years of follow-up of 7457 middle-aged men in Goteborg, Sweden. Stroke 2006, 37:1663-1667.
2. Brass L.M., Isaacsohn J.L., Merikangas K.R., Robinette C.D. A study of twins and stroke. Stroke 1992, 23:221-223.
3. Lusis A.J., Attie A.D., Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 2008, 8:819-830.
4. Yang X., So W.Y., Tong P.C.Y., et al. Development and validation of an all-cause mortality risk score in type 2 diabetes: The Hong Kong diabetes registry. Arch Intern Med 2008, 168:451-457.
5. Song X.Y., Lee S.Y., Ma R.C., et al. Phenotype-genotype interactions on renal function in type 2 diabetes: an analysis using structural equation modeling. Diabetologia 2009, 52:1543-1553.
6. Ma Y.C., Zuo L., Chen J.H., et al. Modified glomerular filtration rate estimating equation for chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2937-2944.
7. Cheng S., Grow M.A., Pallaud C., et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999, 9:936-949.
8. Sladek R., Rocheleau G., Rung J., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
9. Purcell S., Cherny S.S., Sham P.C. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
10. Yang Q., Khoury M.J., Friedman J.M., Little J., Flanders W.D. How many genes underlie the occurrence of common complex diseases in the population?. Int J Epidemiol 2005, 34:1129-1137.
11. Stein M.L., Villanueva J.M., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008, 121:1473-1483.
12. Lee J.H., Chang H.S., Kim J.H., et al. Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients. J Allergy Clin Immunol 2007, 120:1110-1117.
13. Sämpi M., Ukkola O., Päivänsalo M., et al. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J Am Coll Cardiol 2008, 52:1370-1378.
14. Santoro S.A., Zutter M.M. The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost 1995, 74:813-821.
15. Kunicki T.J., Kritzik M., Annis D.S., Nugent D.J. Hereditary variation in platelet integrin alpha 2beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997, 89:1939-1943.
16. Moshfegh K., Wuillemin W.A., Redondo M., et al. Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control study. Lancet 1999, 353:351-354.
17. Nikolopoulos G.K., Tsantes A.E., Bagos P.G., Travlou A., Vaiopoulos G. Integrin alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Thromb Res 2007, 119:501-510.
18. Roest M., Banga J.D., Grobbee D.E., et al. Homozygosity for 807 T polymorphism in alpha(2) subunit of platelet alpha(2)beta(1) is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000, 102:1645-1650.
19. Le Pape A., Guitton J.D., Gutman N., et al. Nonenzymatic glycosylation of collagen in diabetes: incidence on increased normal platelet aggregation. Haemostasis 1983, 13:36-41.
20. Preiss-Landl K., Zimmermann R., Hämmerle G., Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002, 13:471-481.
21. Ross C.J.D., Liu G., Kuivenhoven J.A., et al. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPL S447X beneficial mutation. Arterioscler Thromb Vasc Biol 2005, 25:2143-2150.
22. Wittrup H.H., Tybjærg-Hansen A., Nordestgaard B.G. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation 1999, 99:2901-2907.
23. Myllykangas L., Polvikoski T., Sulkava R., et al. Association of lipoprotein lipase ser447ter polymorphism with brain infarction: a population-based neuropathological study. Ann Med 2001, 33:486-492.
24. Morrison A.C., Ballantyne C.M., Bray M., et al. LPL polymorphism predicts stroke risk in men. Genet Epidemiol 2002, 22:233-242.
25. Clee S.M., Bissada N., Miao F., et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000, 41:521-531.
26. Luvara G., Pueyo M.E., Philippe M., et al. Chronic blockade of no synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin ii antagonism. Arterioscler Thromb Vasc Biol 1998, 18:1408-1416.
27. Veldman B.A., Spiering W., Doevendans P.A., et al. The glu298asp polymorphism of the nos 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002, 20:2023-2027.
28. Lembo G., De Luca N., Battagli C., et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001, 32:735-740.
29. Casas J.P., Cavalleri G.L., Bautista L.E., et al. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a huge review. Am J Epidemiol 2006, 164:921-935.
30. Berger K., Stögbauer F., Stoll M., et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet 2007, 121:169-178.